Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2026—Cystatin C has notable advantages over serum creatinine as a biomarker of kidney filtration: fewer nonglomerular filtration rate determinants, more accurate dosing of medications with narrow therapeutic windows for individuals with obesity or low muscle mass, and greater accuracy in determining eligibility for a kidney transplant or for a simultaneous liver-kidney or heart-kidney transplant.
May 2026—The fast-changing world of sequencing was the topic that a panel of pathologists and industry representatives dug into in a Feb. 27 online roundtable, led by CAP TODAY publisher Bob McGonnagle.
May 2026—The Papanicolaou test has been a model for cancer screening and prevention since its introduction well over half a century ago. Despite the evolution and innovations in HPV vaccination, testing methodologies, reporting systems, and treatment algorithms, cervicovaginal and lower genital tract cytology continues to be a workhorse for providers and laboratories.
May 2026—Digital pathology has evolved substantially over the past decade. What started primarily as a platform for image storage now supports educational initiatives, remote signout, consultation, and image analysis deployment.
May 2026—Education is one of the CAP’s core missions, closely linked to its commitment to advocacy and excellence in practice. In addition to its overarching laboratory improvement programs, the CAP provides educational offerings in a variety of formats, designed to satisfy the learning needs of its members and of a diverse group of laboratory professionals.
May 2026—The CAP recently reached a record high of over 20,000 members, strengthening its advocacy efforts. Through PathPAC, the CAP engages with federal policymakers to advocate for pathologists and patient care. The CAP also advocates for the pathology community through its involvement with the AMA.
May 2026—Use of AI to define spatial patterns of tumor-infiltrating lymphocytes associated with patient outcome; Expanding the clinicopathologic spectrum of EWSR1::SSX-rearranged sarcomas
May 2026—Training in cell and gene therapy manufacturing via graduate medical education; Phase one trial of CRISPR-Cas9 gene editing targeting ANGPTL3
May 2026—Role of genetics and environment in shaping the human immune cell epigenome; Update on MRD in acute myeloid leukemia: a consensus document
May 2026
Q. When we receive new immunohistochemistry antibodies or DAB kits, they undergo a quality control process. Every institution where I have worked has done this task a little differently. When a laboratory receives a new antibody, what is the correct QC process? What if we receive two units of the same antibody from the same lot but one came in on Thursday and one on Friday? Read answer.
